Astrazeneca (AZN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.63
- EPS estimate
- $2.48
- EPS surprise
- +6.21%
- Revenue surprise
- −0.33%
- Revenue
- $15.4B
- Revenue estimate
- $15.4B
- Reported
- Jul 27, 2026
AstraZeneca reported Q2 2026 results on July 27, 2026. Earnings per share were $2.63, ahead of the $2.48 estimate by 6.21%. Revenue was $15.4 billion, in line with the $15.4 billion consensus. Compared with Q2 2025, EPS rose about 21% from $2.17, and revenue rose about 6% from $14.5 billion. The quarter's EPS was the highest in the table.
The table covers 10 quarters, from Q1 2024. Annual EPS rose from $8.21 in 2024 to $9.16 in 2025, about 12% higher. The first half of 2026 adds up to $5.21, about 12% above the $4.66 of the first half of 2025. Quarterly revenue climbed from $12.7 billion in Q1 2024 to between $15.2 and $15.5 billion over the last four quarters. AstraZeneca beat the EPS estimate in all 10 quarters. From Q1 2024 to Q3 2025, though, the estimates shown were about half of reported EPS, so the surprises of over 100% in those rows are not comparable with the smaller beats since.
AstraZeneca reported Q3 on November 12, 2024 and November 6, 2025. That points to early or mid-November 2026 for the next report. It will show whether EPS stays above the $2.38 of Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 27, 2026 | $2.48 | $2.63 | +6.21% | $15.4B | SEC |
| Q1 2026 | Apr 29, 2026 | $2.51 | $2.58 | +2.60% | $15.3B | SEC |
| Q4 2025 | Feb 10, 2026 | $2.11 | $2.12 | +0.71% | $15.5B | SEC |
| Q3 2025 | Nov 6, 2025 | $1.15 | $2.38 | +107.61% | $15.2B | SEC |
| Q2 2025 | Jul 29, 2025 | $1.08 | $2.17 | +100.89% | $14.5B | SEC |
| Q1 2025 | Apr 29, 2025 | $1.13 | $2.49 | +121.02% | $13.6B | SEC |
| Q4 2024 | Feb 6, 2025 | $1.04 | $2.09 | +101.93% | $14.9B | SEC |
| Q3 2024 | Nov 12, 2024 | $1.02 | $2.08 | +103.66% | $13.6B | SEC |
| Q2 2024 | Jul 25, 2024 | $0.98 | $1.98 | +101.49% | $12.9B | SEC |
| Q1 2024 | Apr 25, 2024 | $0.96 | $2.06 | +115.59% | $12.7B | SEC |
Quarterly revenue
Frequently asked questions
When did Astrazeneca (AZN) last report earnings?
Astrazeneca last reported on Jul 27, 2026, covering fiscal Q2 2026.
Did AZN beat earnings estimates?
Yes. Astrazeneca reported EPS of $2.63 for Q2 2026 against a $2.48 estimate — a 6.21% beat.
How much revenue did AZN report last quarter?
Astrazeneca reported $15.4B in revenue for Q2 2026, against a consensus estimate of $15.4B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.